TY - JOUR T1 - Biomarkers for immunotherapy in bladder cancer: a moving target JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1186/s40425-017-0299-1 VL - 5 IS - 1 SP - 94 AU - David H. Aggen AU - Charles G. Drake Y1 - 2017/12/01 UR - http://jitc.bmj.com/content/5/1/94.abstract N2 - Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1 antibody pembrolizumab demonstrated improved OS relative to chemotherapy in a randomized phase III study for second line treatment of mUC; this level 1 evidence led to approval from the U.S. Food and Drug Administration (FDA). The PD-1 antibody nivolumab also demonstrated an overall survival benefit, in this case in comparison to historical controls. Similarly, antibodies targeting PD-L1 including atezolizumab, durvalumab, and avelumab have now received accelerated approval from the FDA as second line treatments for mUC, with durable response lasting more than 1 year in some patients. Some of these agents are approved in the first line setting as well - based on single-arm phase II studies atezolizumab and pembrolizumab received accelerated approval for first-line treatment of cisplatin ineligible patients. Despite these multiple approvals, the development of clinically useful biomarkers to determine the optimal treatment for patients remains somewhat elusive. In this review, we examine key clinical trial results with anti-PD1/PD-L1 antibodies and discuss progress towards developing novel biomarkers beyond PD-L1 expression.Abbreviations:AEAdverse eventCIConfidence intervalFDAFood and Drug AdministrationICImmune cellIHCImmunohistochemistryMSIMicrosatellite instabilitymUCMetastatic urothelial cancerNSMNon synonomous mutationORRObjective response rateOSOverall survivalPD-1Programmed cell death protein 1PD-L1Programmed death ligand 1PFSProgression-free survivalTCTumor cellTCGAThe Cancer Genome AtlasTMBTumor mutation burden ER -